<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02862171</url>
  </required_header>
  <id_info>
    <org_study_id>IPM 032</org_study_id>
    <nct_id>NCT02862171</nct_id>
  </id_info>
  <brief_title>To Assess Continued Safety of and Adherence to the Dapivirine (25 mg) Vaginal Ring-004 in Healthy, HIV-negative Women</brief_title>
  <official_title>A Follow-On, Open-Label Trial To Assess Continued Safety Of And Adherence To The Dapivirine (25 Mg) Vaginal Ring-004 In Healthy, HIV-Negative Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Partnership for Microbicides, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>International Partnership for Microbicides, Inc.</source>
  <brief_summary>
    <textblock>
      A follow-on, open label trial to assess continued safety of and adherence to the
      Dapivirine(25mg) vaginal ring-004 in healthy, HIV-negative women
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 13, 2016</start_date>
  <completion_date type="Actual">December 10, 2018</completion_date>
  <primary_completion_date type="Actual">December 10, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gynaecological assessments including pelvic/speculum examination.</measure>
    <time_frame>12 months</time_frame>
    <description>To assess the safety profile of the 25 mg Dapivirine Vaginal Ring-004, when inserted at monthly intervals, in an open-label trial</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determined dapivirine residual amounts in returned used vaginal rings and/or Measured concentrations of dapivirine in plasma and/or vaginal fluids</measure>
    <time_frame>12 months</time_frame>
    <description>To assess adherence to the use of the 25 mg Dapivirine Vaginal Ring-004 inserted at monthly intervals, in an open-label trial</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rapid and specialised laboratory testing according to a pre-specified HIV testing algorithm</measure>
    <time_frame>12 months</time_frame>
    <description>To assess the incidence of HIV-1 seroconversion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral genotype resistance testing methods</measure>
    <time_frame>12 months</time_frame>
    <description>To assess the frequency of HIV-1 drug resistance in women who acquire HIV-1 infection</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">850</enrollment>
  <condition>HIV Prevention</condition>
  <arm_group>
    <arm_group_label>Dapivirine Vaginal Ring-004</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapivirine Vaginal Ring, 25 mg.Each participant will engage in the screening process for up to 45 days prior to enrolment and will use the monthly Dapivirine Vaginal Ring for a period of up to 12 months. IPM will have the option to extend this trial period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapivirine Vaginal Ring-004</intervention_name>
    <description>To assess the safety profile of the 25 mg Dapivirine Vaginal Ring-004, when inserted at monthly intervals, in an open-label trial</description>
    <arm_group_label>Dapivirine Vaginal Ring-004</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Women must meet all the following criteria to be eligible to enrol in the trial:

          1. Previously enrolled in the IPM 027 trial

          2. Available for all visits and consent to follow all procedures scheduled for the trial

          3. Using an effective method of contraception at the Enrolment Visit, and intending to
             use an effective contraceptive method for the duration of trial participation, unless
             post-menopausal with no history of menses for one year prior to screening

          4. HIV-negative as determined by the HIV algorithm applied at Screening/Pre- Enrolment

          5. Willing to refrain from participation in another research trial using drugs, vaccines,
             medical devices and microbicides for the duration of the IPM 032 trial

          6. Willing to provide adequate locator information for trial retention purposes and be
             reachable per local standard procedures (e.g., by home visit or telephone; or via
             family or close neighbour contacts); confidentiality to be maintained.

        Exclusion Criteria:

        Women who meet any of the following criteria are NOT eligible to enrol in the trial:

          1. Investigational product use permanently discontinued in response to an AE (where the
             AE was considered related to investigational product) or safety-related concern while
             taking part in the IPM 027 trial

          2. Participant self-report of taking post-exposure prophylaxis (PEP) within â‰¤ 2 months at
             Screening Visit Note: Participants may be enrolled after completing the PEP regimen
             and a negative HIV test was documented at least 2 months prior to screening for IPM
             032

          3. Currently pregnant, intends to become pregnant or currently breast-feeding

          4. Known drug abuse or alcohol dependence in the 12 months prior to screening

          5. Participated in another research trial (other than IPM 027) using drugs, medical
             devices, microbicides or oral pre-exposure prophylaxis agents within 30 days prior to
             screening

          6. Any new illness or condition(s), chronic condition(s) or abnormal laboratory
             finding(s) that, in the opinion of the investigator, might put the participant at
             risk, or interfere with the trial objectives or the participant's adherence to trial
             requirements
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Madibeng Centre for Research</name>
      <address>
        <city>Brits</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desmond Tutu HIV Foundation</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ndlovu Medical Centre</name>
      <address>
        <city>Elandsdoorn</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qhakaza Mbokodo</name>
      <address>
        <city>Ladysmith</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MatCH Edendale Research Center</name>
      <address>
        <city>Pietermaritzburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MRC/UVRI Uganda Research Unit on AIDS</name>
      <address>
        <city>Entebbe</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
    <country>Uganda</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 25, 2016</study_first_submitted>
  <study_first_submitted_qc>August 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2016</study_first_posted>
  <disposition_first_submitted>February 18, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>February 18, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">February 25, 2020</disposition_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapivirine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

